Mother’s Immune System May Block Fetal Treatments for Blood Diseases
The News Review:
- Mother’s Immune System May Block Fetal Treatments for Blood Diseases
- Helix BioPharma Announces the Appointment of Kazimierz Roszkowski …
- Physicians bust myths about Insulin
- DATATRAK International Inc. Announces 2009 Second Quarter and …
- Scientific Research into Dysphagia Treatment Modality Reaches …
- Take care when discussing phase I trial options
- p-Ed Contributor Clinical Trials Wrapped in Red Tape
Mother’s Immune System May Block Fetal Treatments for Blood Diseases
PR Newswire (press release)
In a new study in animals the researchers showed that the mother’s immune response interferes with the offspring’s earlier ability to tolerate transplanted donor cells. The study team concludes that focusing on transplant techniques that avoid the maternal immune response may allow scientists to take advantage of fetal tolerance to achieve a long-sought goal of treating blood diseases prenatally. While cautioning that much work must be done to understand how these animal findings apply to humans the current findings are “surprising but reassuring” said study leader Alan W. of the Children’s Center for Clinical Research at The Children’s Hospital of Philadelphia. The study appeared online August 3 in the Journal of Clinical Investigation.
Related from Indoorenvirons: Superbugs learning to ‘network’ with human immune system: researcher
Helix BioPharma Announces the Appointment of Kazimierz Roszkowski …
PR Newswire (press release) (press release)
com Editor’s Note: Photograph is available on request This News Release contains certain forward-looking statements and information regarding the Company’s product development initiatives and in particular its L-DS47 new drug candidate which statements and information can be identified by the use of forward-looking terminology such as “continue” “drive” “towards” “forward” “guide” “into and through the clinical development process” “developing” or variations thereon or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix’s actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation the Company’s need for additional capital which if not obtained in a timely manner or at all will have a material adverse impact on the Company its research and development programs and ultimately its ability to continue; the impact of the global economic downturn and credit crisis which have negatively affected the availability of additional capital particularly for development stage biotechnology companies such as Helix; uncertainty whether L-DS47 or Topical Interferon Alpha-2b will be successfully developed and commercialized as a drug or at all; the need for additional pre-clinical and clinical research and development which may not be successful or completed in a timely manner; manufacturing and upscaling risks including the possibility that further challenges may arise in connection with the manufacture of clinical batches of L-DS47 or Topical Interferon Alpha-2b which could further delay or otherwise negatively affect the Company’s planned development programs; the risk of obtaining negative findings or factors that may become apparent during the course of research or development which may result in the discontinuation or delay of the research or development projects; the need for future clinical trials the occurrence and success of which cannot be assured; product liability and insurance risks; the risk of technical obsolescence; the need for further regulatory approvals which may not be obtained in a timely matter or at all; intellectual property risks; Helix’s dependence on numerous third parties including without limitation contract research organizations contract manufacturing organizations clinical trial consultants collaborative research consultants regulatory affairs advisors and others whose performance and interdependence can critically affect the Company’s performance and the achievement of its milestones; Helix’s dependence on its licensor of the L-DS47 antibody and on the antibody license granted to Helix for the continued development of L-DS47; the need to secure new strategic relationships which is not assured to commercialize L-DS47 and any other drug candidates which may arise out of DS47; the risk that the Company’s license optionee for Topical Interferon Alpha-2b may not continue to provide the Company with interferon alpha-2b or exercise its option which would have a negative effect on the further development of the drug candidate and on the Company; the risk of unanticipated expenses or unanticipated reductions in revenue or both; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix’s products; and the risk of changes in business strategy or development plans. Such risks and uncertainties and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information are more fully described in the Company’s latest Annual Information Form MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at.
Physicians bust myths about Insulin
24 Medica
Lingvay said is to begin analyzing how the insulin plus metformin and oral triple therapy regimens affect insulin production in beta cells. ther UT Southwestern researchers involved in the study included Jaime Legendre recipient of a Clinical Research Fellowship from the Doris Duke Charitable Foundation; Dr. Polina Kaloyanova former fellow in endocrinology; Dr. Song Zhang assistant professor of clinical sciences; and Beverley Adams Huet assistant professor of clinical sciences. The study was supported by Novo Nordisk Inc. the National Institutes of Health and the Doris Duke Charitable Foundation.
DATATRAK International Inc. Announces 2009 Second Quarter and …
PR Newswire (press release)
Backlog consists of anticipated revenue from authorization letters to commence services statements of work and other signed contracts yet to be completed. Potential contracts or authorization letters that have passed the verbal stage but have not yet been signed are excluded from backlog. The June 30th backlog figure does not reflect the previously announced signing of a letter of intent with a leading global clinical research organizations (CR) for trial services on a Phase III trial awarded to DATATRAK by the European division of a Global Top 20 Pharmaceutical company in July with an estimated backlog amount of $745000. During the quarter the Company’s cash balance declined to $1. 63 million at June 30 2009 compared to $2. 08 million as of March 31 2009. Approximately 47% of the $446000 cash decrease or $208000 is attributable to the payment of severance commitments primarily to former executive officers of the Company.
Scientific Research into Dysphagia Treatment Modality Reaches …
Advertiser Talk
The paper “Neuromuscular Electrical Stimulation in the Treatment of Dysphagia: A Summary of the Evidence” shows that the scientific data has proliferated over the past two years at an unprecedented rate. Neuromuscular Electrical Stimulation (NMES) used as an adjunct modality in the treatment of dysphagia has gained increasing adoption by medical professionals since the clearance by the Food and Drug Administration of VitalStim® Therapy the only device on the market with such clearance. (FDA 2002) According to Yorick Wijting director of clinical research for VitalStim “The need for clinical data to support the efficacy of electrical stimulation in the continuing treatment of dysphagia is being satisfied by independent medical researchers around the world. “Research activity in this area is unparalleled in the history of dysphagia research. Available data now provide substantial scientific and clinical support for the addition of electrotherapy in the treatment of dysphagia to enhance treatment outcomes. In actual fact available evidence supporting the use of NMES for dysphagia at present exceeds the evidence supporting other reimbursable interventions used in the treatment of dysphagia. ” Use of NMES in the treatment of dysphagia involves the administration of small electrical impulses to swallowing muscles in the throat through electrodes attached to the skin overlying the musculature.
Take care when discussing phase I trial options
American Medical News
This topic continues to spark controversy for two important reasons: the frequent exhaustion of the few standard treatment options available for many patients with advanced cancers and several common yet fundamental misconceptions about phase I trials and their goals. Due to the lack of expected benefit to the immediate participant and the trials’ controversial nature an oncologist who decides not to raise the possibility of phase I studies with some patients has not violated professional obligations or ethics. In fact discussing phase I trials with every patient may have unintended negative consequences for some particularly if their decision comes at the expense of more intensive palliation or even a hospice referral. See related content.
p-Ed Contributor Clinical Trials Wrapped in Red Tape
New York Times
Stanford University researchers have estimated that it cost them about $56000 in administrative wages 18 months of delay and 10000 pages of paper to make a small change to an already-approved research program that simply compared the progress made by patients attending different types of addiction-treatment programs. The lengthy approval process cuts into scientific productivity. David Dilts the director of clinical research at the Knight Cancer Institute in regon found that 30 percent of all board-approved oncology trials are eventually abandoned. To circumvent overbearing federal boards researchers occasionally turn to for-profit independent review boards to approve their studies. These boards cost less and work quickly but some have dangerously lax standards. This spring the Government Accountability ffice announced that it had submitted a fabricated study of a fake surgical adhesive gel called Adhesiabloc to an independent review board which approved the protocol by unanimous vote saying the “gel is probably very safe. ” Even if a study gets approval from an institutional review board it’s not clear that the subjects are all that protected.
Written by admin on August 17th, 2009 with
no comments.
Read more articles on News.